EE438 Assessing the Cost-Effectiveness of Axicabtagene Ciloleucel Compared With Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in the UK
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.683
https://www.valueinhealthjournal.com/article/S1098-3015(22)02887-X/fulltext
Section Title :
Section Order :
10222
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02887-X&doi=10.1016/j.jval.2022.09.683